MX2017002705A - Sondas para la proyección de imagen de la proteína huntingtina. - Google Patents

Sondas para la proyección de imagen de la proteína huntingtina.

Info

Publication number
MX2017002705A
MX2017002705A MX2017002705A MX2017002705A MX2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A
Authority
MX
Mexico
Prior art keywords
probes
huntingtin protein
imaging
imaging huntingtin
protein
Prior art date
Application number
MX2017002705A
Other languages
English (en)
Spanish (es)
Inventor
Dominguez Celia
John Brown Christopher
Wityak John
Bard Jonathan
Edward Prime Michael
David Johnson Peter
Clark Frew Daniel
Rene Gabriel Galan Sebastien
Richard Giles Paul
Alexander Weddell Derek
Simon Walter Daryl
James WIGGINTON Ian
George Taylor Malcolm
Martin KRÜLLE Thomas
Morao Inaki
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017002705A publication Critical patent/MX2017002705A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6823Release of bound markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0412Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
MX2017002705A 2014-08-29 2015-08-28 Sondas para la proyección de imagen de la proteína huntingtina. MX2017002705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043617P 2014-08-29 2014-08-29
PCT/US2015/047427 WO2016033460A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
MX2017002705A true MX2017002705A (es) 2017-12-20

Family

ID=55400659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002705A MX2017002705A (es) 2014-08-29 2015-08-28 Sondas para la proyección de imagen de la proteína huntingtina.

Country Status (14)

Country Link
US (1) US10907197B2 (enExample)
EP (1) EP3190888B1 (enExample)
JP (1) JP2017528520A (enExample)
KR (1) KR20170047341A (enExample)
CN (1) CN107105655A (enExample)
AU (2) AU2015308709B2 (enExample)
BR (1) BR112017004134A2 (enExample)
CA (1) CA2959505A1 (enExample)
EA (1) EA201790408A1 (enExample)
ES (1) ES2818107T3 (enExample)
IL (1) IL250804A0 (enExample)
MX (1) MX2017002705A (enExample)
SG (1) SG11201701580XA (enExample)
WO (1) WO2016033460A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
CN106632002A (zh) * 2016-09-28 2017-05-10 贵州大学 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CA3190418A1 (en) * 2020-08-06 2022-02-10 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging huntingtin protein
WO2022216947A1 (en) * 2021-04-08 2022-10-13 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1367836A (en) * 1918-04-29 1921-02-08 Int Precipitation Co Process for obtaining chlorids of potassium or other metals
US3985755A (en) * 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
FR2524468B1 (fr) * 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JPS60146877A (ja) * 1984-01-11 1985-08-02 Chisso Corp 2―置換―6―(5―置換―2―ピリミジニル)ナフタリン
JPH11171886A (ja) * 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
UA78536C2 (en) * 2001-12-20 2007-04-10 Wyeth Corp Indolylalkylamine derivatives as ligands of 5-hydroxytryptamine-6, method of production (variants), pharmaceutical composition
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1611115B1 (en) * 2003-03-14 2012-08-22 University of Pittsburgh - of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
WO2008022396A1 (en) 2006-08-24 2008-02-28 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
US20090123373A1 (en) 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) * 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
ES2554772T3 (es) 2008-05-30 2015-12-23 Merck Sharp & Dohme Corp. Azabenzoxazoles sustituidos novedosos
JP2012507534A (ja) 2008-10-31 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 新規置換アザベンゾオキサゾール類
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2010112874A1 (en) * 2009-04-02 2010-10-07 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
GB0905664D0 (en) 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Also Published As

Publication number Publication date
SG11201701580XA (en) 2017-03-30
ES2818107T3 (es) 2021-04-09
CN107105655A (zh) 2017-08-29
WO2016033460A1 (en) 2016-03-03
BR112017004134A2 (pt) 2017-12-12
AU2015308709B2 (en) 2020-01-02
US10907197B2 (en) 2021-02-02
EA201790408A1 (ru) 2017-09-29
EP3190888B1 (en) 2020-06-10
KR20170047341A (ko) 2017-05-04
JP2017528520A (ja) 2017-09-28
IL250804A0 (en) 2017-04-30
CA2959505A1 (en) 2016-03-03
EP3190888A4 (en) 2018-05-09
AU2020202226A1 (en) 2020-04-16
AU2015308709A1 (en) 2017-03-23
EP3190888A1 (en) 2017-07-19
US20170292150A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
MX2021003311A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
TW201613872A (en) IRAK4 inhibiting agents
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX386798B (es) Sondas para la proyección de imagen de la proteína huntingtina.
ZA201708417B (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CY1121464T1 (el) Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
IL259952A (en) Use of tryptophan derivatives for protein formulations
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EP3218721A4 (en) Compounds for use as imaging agents
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
SI3652187T1 (sl) Izboljšan postopek za pripravo imetelstata
IL246835A0 (en) Improved process for the preparation of trazodone and its hydrochloride salt
WO2015179349A3 (en) Synthesis of beta-arrestin effectors
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
IT201700024657A1 (it) Materassino per operazioni chirurgiche.
HK1236113A1 (en) Synthesis of beta-arrestin effectors